The present disclosure relates to
epitope peptides for tumor-associated antigens and use thereof. The
epitope peptides for tumor-associated antigens are derived from embryonic stem cells, and NUF-2. Studies have found that among
embryonic stem cell-derived tumor-associated antigens selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2, the tumor-associated antigens KIF4A and NUF-2 expressed by embryonic stem cells (ESCs) can effectively inhibit the growth of
bladder cancer, and the tumor-associated antigens CENPM, NUF-2, and IQGA3 expressed by the ESCs can strongly stimulate the immune response of specific T cells, which is manifested by stimulating
peptide-specific CTL to secrete high levels of IFN-γ and inhibiting
tumor growth, and the
epitope peptides for tumor-associated antigens can be used in the preparation of a medicament for inhibiting the growth of
tumor cells or stimulating immune cells to produce a
T cell response.